drugset / Trial / NCT03717142
Feasibility of the LUM Imaging System for Detection of Cancer to the Brain
Non-randomizedSequentialOpen-labelDevice feasibility
Summary
The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cancer masses that have metastasized to the brain.
Timeline
- Start
- 2019-05-03
- Primary completion
- 2023-09-13
- Completion
- 2024-06-14
Outcome
Outcome not reported
Stopped: “Initial data indicated a change in study design required prior to collecting additional data.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGULICIANINE ACETATE | Diagnostic / imaging agent | 1 mg/kg | Intravenous |
| Subject | PEGULICIANINE ACETATE | Diagnostic / imaging agent | 2 mg/kg | Intravenous |
| Subject | PEGULICIANINE ACETATE | Diagnostic / imaging agent | 3 mg/kg | Intravenous |